Abstract
THE LONG-AWAITED acellular pertussis vaccines are about to become available for use in the fourth and fifth doses of the childhood diphtheria-tetanus-pertussis (DTP) immunization schedule. Although there is no move at present to incorporate the acellular form of the vaccine into the first three doses of the routine childhood DTP immunization schedule, the coming licensure of these vaccines marks the first step toward their eventual availability for the entire DTP schedule. Studies are being done by manufacturers and the National Institutes of Health, Bethesda, Md, to test the safety and efficacy of these acellular agents when used in the first three doses. In the meantime, an advisory committee of the Food and Drug Administration, Rockville, Md, having heard evidence from two manufacturers— Lederle Laboratories, Wayne, NJ, and Connaught Laboratories, Swiftwater, Pa—that the acellular vaccines are at least as immunogenic as the whole-cell product and have fewer untoward reactions, recommended fourth
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.